Dana Pizzuti - Mar 20, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Med and Dev Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Mar 20, 2024
Transactions value $
-$421,970
Form type
4
Date filed
3/22/2024, 04:52 PM
Previous filing
Mar 20, 2024
Next filing
Apr 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $73.9K +4.38K +15.35% $16.89 32.9K Mar 20, 2024 Direct
transaction CRNX Common Stock Sale -$201K -4.38K -13.31% $45.89 28.5K Mar 20, 2024 Direct
transaction CRNX Common Stock Options Exercise $169K +10K +35.09% $16.89 38.5K Mar 20, 2024 Direct
transaction CRNX Common Stock Sale -$433K -10K -25.97% $43.28 28.5K Mar 20, 2024 Direct F1
transaction CRNX Common Stock Sale -$31.2K -714 -2.51% $43.69 27.8K Mar 20, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Options Exercise $0 -4.38K -2.12% $0.00 202K Mar 20, 2024 Common Stock 4.38K $16.89 Direct F2
transaction CRNX Stock Option (right to buy) Options Exercise $0 -10K -4.96% $0.00 192K Mar 20, 2024 Common Stock 10K $16.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.28 per share. The range of sales prices on the transaction date was $42.70 to $43.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.